
Opinion|Videos|December 6, 2024
Managing Cognitive and Sexual Health in Prostate Cancer Patients on Hormonal Therapy
Key Takeaways
- Early and aggressive treatment strategies are crucial for improving outcomes in high-risk metastatic castration-sensitive prostate cancer.
- Combining androgen deprivation therapy with novel hormonal agents or chemotherapy enhances survival rates.
Panelists discuss how managing cognitive and sexual health in prostate cancer patients undergoing hormonal therapy is crucial, emphasizing the need for proactive communication and tailored interventions to enhance overall quality of life.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Finally, to close out, which clinical pearls would you like to share with other health care providers who treat patients with high-risk metastatic castration-sensitive prostate cancer?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Sildenafil cream for female sexual arousal disorder available to prescribe in select states
2
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
3
Experts urge FDA to revisit labeling for testosterone replacement therapy in men
4
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
5














